August 29, 2017 / 9:29 PM / 10 months ago

D.C. Circuit rejects Otsuka bid to take Abilify rival off the market

A federal appeals court has refused to revive a lawsuit by Otsuka Pharmaceutical Co seeking to take a competitor of its injectable schizophrenia drug Abilify Maintena off the market.

The U.S. Court of Appeals for the D.C. Circuit on Tuesday agreed that the Food and Drug Administration was justified in finding that Otsuka’s statutory exclusivity period for Abilify Maintena does not block a similar drug with a different active ingredient made by rival Alkermes PLC.

To read the full story on WestlawNext Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below